274. Osteogenesis Imperfecta Clinical trials / Disease details
Clinical trials : 91 / Drugs : 101 - (DrugBank : 20) / Drug target genes : 11 - Drug target pathways : 48
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05559801 (ClinicalTrials.gov) | March 2023 | 8/9/2022 | Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI) | A Phase 1/2 Study to Examine the Safety and Preliminary Efficacy of Mesenchymal Stromal Cells on Linear Growth and Bone Health Parameters in Children With Type 3 Osteogenesis Imperfecta (OI) | Osteogenesis Imperfecta;Osteogenesis Imperfecta Type III | Drug: Bone marrow-derived mesenchymal stromal cells (MSCs) | Emory University | NULL | Not yet recruiting | 3 Years | 10 Years | All | 12 | Phase 1/Phase 2 | NULL |